Medications in the School Setting. Kristen Nichols, PharmD, BCPS-AQ ID Butler University Riley Hospital for Children
|
|
- Catherine Cobb
- 5 years ago
- Views:
Transcription
1 Medications in the School Setting Kristen Nichols, PharmD, BCPS-AQ ID Butler University Riley Hospital for Children
2 OBJECTIVES Discuss treatment options for treatment of attention-deficit/hyperactivity disorder Identify medications used for psychiatric conditions in children and adolescents and their adverse effects Describe use of benzodiazepines for acute treatment of seizures Recognize limitations of antibiotic medications
3 COMMONLY PRESCRIBED MEDICATIONS 2-11 Years Amoxicillin Azithromycin Albuterol Montelukast Methylphenidate Fluticasone Prednisolone Cefdinir Cephalexin Amoxicillin/clavulanate Years Methylphenidate Albuterol Azithromycin Amoxicillin Amphetamine/dextroamphetamine Montelukast Norgestimate-ethinyl estradiol Lisdexamfetamine Fluticasone Hydrocodone/acetaminophen Chai et al. Pediatrics. 130(1): Antibiotics, stimulants, asthma/allergy
4 TODAY S DISCUSSION ADHD Depression/anxiety Other behavioral medications Seizure rescue medications Rectal diazepam & intranasal midazolam Antibiotics
5 Attention Deficit Hyperactivity Disorder Stimulant use increased from 2002 to 2010
6 Evaluate individuals 4-18 years with: Academic or behavioral problems AND Symptoms of inattention, hyperactivity, or impulsivity Obtain information from Family School Child Meet DSM-V criteria Subcommittee on ADHD. Pediatrics. 2011;128:
7 ADHD TREATMENT 4-5 years 1 st : Parent or teacher-administered behavior therapy 2 nd : Methylphenidate 6-11 years FDA-approved medications and/or Behavior therapy Preferably BOTH years Medications WITH assent and Behavior therapy (maybe) Preferably both Subcommittee on ADHD. Pediatrics. 2011;128:
8 4-5 YEAR OLDS: METHYLPHENIDATE Technically off-label Most data for safety & efficacy in this age group Decreased metabolism compared to older children Start low Titrate in smaller increments Methylin (+generics) Quillivant XR AGE-APPROPRIATE DOSAGE FORMS IR oral solution: 5 mg/5 ml; 10 mg/5 ml Chewable tablet: 2.5 mg, 5 mg, 10 mg XR oral solution: 25 mg/5 ml IR=immediate release XR = extended-release Subcommittee on ADHD. Pediatrics. 2011;128:
9 START WITH A STIMULANT FROM EITHER CLASS Amphetamine compounds Methylphenidate products Mixed amphetamine salts Methylphenidate Dextroamphetamine Dexmethylphenidate Lisdexamfetamine Subcommittee on ADHD. Pediatrics. 2011;128:
10 PRODUCT CONSIDERATIONS When is coverage needed? Time to onset Duration of effect Dosage Forms ER/XR dosage forms should not be chewed, crushed, divided Cost Convenience Abuse potential? Can be given just on school days
11 CARDIOVASCULAR RISK Sudden cardiac death is rare Uncertain association Baseline ECG: AAP doesn t recommend AHA says it is reasonable Evaluate cardiac history at baseline Congenital heart disease or cardiac abnormality: collaboration between family, ADHD specialist, pediatric cardiologist BP and HR s are usually mild Cortese et al. J Child Psychol Psychiatry 2013;54(3)
12 ADDITIONAL ADVERSE EFFECTS (STIMULANTS) appetite growth velocity Abdominal pain Headaches Insomnia Irritability Emotional lability Abuse potential Xerostomia Worsen tics Visual disturbance FDA Warning: sustained or prolonged erections Subcommittee on ADHD. Pediatrics. 2011;128: Cortese et al. J Child Psychol Psychiatry 2013;54(3)
13 STIMULANTS WITH LESS ABUSE POTENTIAL Lisdexamfetamine (Vyvanse ): Metabolized after ingestion by erythrocyte cells to dexamphetamine Dermal methylphenidate (Daytrana ): Difficult to extract the medication; mixed into the adhesive along with silicone & acrylic OROS methylphenidate (Concerta ): Difficult to extract medication; ~20% in outer coating; remaining slowly released from small hole in core over 12H Subcommittee on ADHD. Pediatrics. 2011;128:
14 NEXT STEPS Non-response: Try other stimulant class Up to 50% of non-responders will respond Adverse effects: Try other stimulant class Partial response: ER guanfacine & clonidine approved as adjunctive therapy Refusal of stimulant or diversion potential Atomoxetine Subcommittee on ADHD. Pediatrics. 2011;128:
15 TX CHILDREN S MED ALGORITHM PROJECT After trying both stimulant classes: Atomoxetine Bupropion or tricyclic antidepressant Bupropion or tricyclic antidepressant (opposite) Alpha agonists (clonidine & guanfacine) Pliszka SR et al. J Am Acad Child Adolesc Psychiatry. 2006;45(6):64-657
16 AAP ADHD GUIDELINES No specific algorithm after stimulants Strength of data: Atomoxetine ER guanfacine ER clonidine Subcommittee on ADHD. Pediatrics. 2011;128:
17 ATOMOXETINE Selective norepinephrine-reuptake inhibitor Improves comorbid tics Maximum effect in 4-6 weeks Potential drug interactions Capsules only Adverse effects: Risk of suicidal ideation during initiation in BP & HR; cardiovascular events? Somnolence Appetite & growth suppression Pediatric and Neonatal Lexi-Drugs Online
18 BUPROPION Not FDA approved or in AAP guidelines Weak inhibitor of norepinephrine & dopamine IR & SR/XL tablets (start with IR & titrate) Don t crush or chew SR/XL dosage forms Adverse effects Risk of suicidal ideation during initiation Anxiety/insomnia/activation BP Lower seizure threshold Pediatric and Neonatal Lexi-Drugs Online
19 ALPHA 2 ADRENERGIC AGONISTS FDA approvals: extended-release formulations Maximum response in 2-4 weeks No breaks, taper when discontinuing BP upon discontinuation, HR GUANFACINE Intuniv & generic Typically better tolerated Longer half-life Sedation Exfoliative rash CLONIDINE Kapvay /Nexiclon XR Available as a liquid Hypotension, bradycardia Sedation Adjunct to stimulants if insomnia Pediatric and Neonatal Lexi-Drugs Online
20 Psychiatry Medications Depression & Anxiety Medications for Autism Spectrum Disorder
21 DEPRESSION Prevalence: % More common in females More common in years Risk factors Family history Early exposure to adversity Psychosocial stressors Traumatic brain injury Gender dysphoria/homosexuality Chronic illness Kreys TM. Pediatric Depression. Pediatric Pharmacotherapy. ACCP
22 DEPRESSION TREATMENT Consider patient-specific factors Psychotherapy/CBT Pharmacotherapy Selective serotonin-reuptake inhibitors (SSRIs) Serotonin-norepinephrine-reuptake inhibitors (SNRIs) Bupropion (dopamine/norepi reuptake inhibitor) Mirtazipine Venlafaxine TCAs/MAOIs not typically recommended Acute, continuation, & maintenance phases Hughes CW et al. J Am Acad Child Adolesc Psychiatry. 2007;46: Birmaher B et al. J Am Acad Child Adolesc Psychiatry. 2007;46:
23 SELECTIVE SEROTONIN-REUPTAKE INHIBITORS First-line Fluoxetine (FDA labeled for 8-18 yrs) Escitalopram (FDA labeled for yrs) Sertraline Citalopram Hughes CW et al. J Am Acad Child Adolesc Psychiatry. 2007;46: Birmaher B et al. J Am Acad Child Adolesc Psychiatry. 2007;46:
24 SSRI Pearls Also useful for anxiety Elimination may be faster in children Usually initiate at lower dose & titrate based on efficacy & tolerability Some may have drug interactions Fluoxetine in AM Sertraline GI effects Do not stop abruptly withdrawal Flu-like symptoms, hyperarousal, insomnia, imbalance Less likely with fluoxetine
25 SUICIDALITY BOXED WARNING Boxed warning following a meta-analysis Applies to all antidepressants for individuals through 24 years of age Discuss risks & benefits prior to initiation Monitor patients on any antidepressants for worsening, suicidality, unusual behavior Weekly meetings with clinician during first month recommended Pediatric and Neonatal Lexi-Drugs Online
26 MEDICATIONS IN AUTISM No medications will address underlying disorder Medications may be used to target specific behaviors or comorbid conditions Should be used in combination with behavioral and educational therapies Ji NY et al. Curr Opin Psychiatry. 2015;28:
27 MEDICATIONS USED IN AUTISM Atypical Antipsychotics SSRIs Depression + CNS Stimulants α 2 agonists Hyperactivity Inattention Repetitive behavior Irritability Aggression Self Injury + + Ji NY et al. Curr Opin Psychiatry. 2015;28:
28 OTHER MEDICATIONS WITH EFFICACY DATA Atomoxetine Oxytocin Valproic acid Melatonin Ji NY et al. Curr Opin Psychiatry. 2015;28:
29 ATYPICAL ANTIPSYCHOTICS FDA approval for indications in ASD: Aripiprazole Risperidone Weigh risks & benefits Adverse effects appetite/weight gain blood glucose lipids Sedation Parkinsonism Tardive dyskinesia Hyperprolactinemia Ji NY et al. Curr Opin Psychiatry. 2015;28: Pediatric and Neonatal Lexi-Drugs Online.
30 OTHER ATYPICAL ANTIPSYCHOTICS Less toxic than typical (1 st generation) antipsychotics Also used for other psychiatric disorders Schizophrenia Bipolar disorder Mood disorders Other agents used Quetiapine (QT prolongation, anticholinergic) Olanzapine (weight gain) Others being studied
31 Seizure Rescue Therapy
32 STATUS EPILEPTICUS Many children continue to experience seizures while on therapy Definition Seizure lasting > 5 min OR 2 discrete episodes without regaining consciousness Support for early intervention: time seizing, difficulty in control Seizures > 5 minutes are less likely to resolve without intervention Harm Cerebral injury Neurologic sequelae in 20% Eiland LS. Seizure Disorders. ACCP Pediatric Pharmacotherapy
33 RESCUE THERAPY Community rescue therapy: Breakthrough seizures Increased seizure activity in patients already receiving anti-epileptic drugs Has been shown to ER visits and improve family QOL Benzodiazepines Quick onset of action Enhance inhibitory effect of GABA Diazepam & midazolam
34 DIASTAT ACUDIAL Prefilled, unit dose, rectal delivery system 2 per pack + 2 packets of lubricating jelly Presentation Doses Rectal Tip Size 2.5 mg 2.5 mg 4.4 cm 10 mg 5, 7.5, 10 mg 4.4 cm 20 mg 12.5, 15, 17.5, 20 mg 6 cm 2-5 yrs: 0.5 mg/kg 6-11 yrs: 0.3 mg/kg 12 yrs: 0.2 mg/kg Diastat Prescribing Information
35 GREEN READY BAND AcuDial is locked in to the correct dose by the pharmacist upon dispensing Verify dose in dose display window Look for green ready band
36 DIASTAT ADMINISTRATION Helpful website: Lay person on side Push up with thumb & pull to remove cap (including seal pin) Lubricate rectal tip with provided jelly Bend upper leg forward to expose rectum Separate buttocks Gently insert tip into rectum (snug rim)
37 DIASTAT ADMINISTRATION Slowly count to 3 for each: Pushing in plunger until it stops Remove syringe from rectum Hold buttocks together to prevent leakage Keep person on side & observe, noting time Disposal: 2.5 mg: discard in a garbage can away from children AcuDial: completely remove plunger, point tip over sink or toilet, replace plunger, push until it stops; THEN discard in a garbage can
38 INTRANASAL MIDAZOLAM Rectal Diazepam Intranasal Midazolam Cost $$$ $ Social Concerns Social concerns/ need for privacy More convenient Abuse potential? Time to Peak 1.5 hours 5 10 minutes Elimination t 1/ hours 3 5 hours Disease Interference Constipation Bowel movement URTI Nasal Congestion Dose prep Remove cap Draw up in syringe Onset 3-4 minutes; data mixed regarding which is faster Holsti et al. Ped Emerg Care. 2007;23:
39 INTRANASAL MIDAZOLAM ~0.2 mg/kg (max 10 mg) Use 5 mg/ml solution for inject Store at room temp Can give ½ in each nare Ideal to use an atomizer Pediatric and Neonatal Lexi-Drugs Online
40 IN MIDAZOLAM ADMINISTRATION Remove vial cap & swab with alcohol Using syringe & needle withdraw desired amount of medication from vial Re-cap & remove needle Twist atomizer onto syringe With child (typically) on back/side, put tip of atomizer into one nostril Press plunger to given ½ Repeat on other side
41 EMERGENCY SEIZURE TREATMENT
42 MONITORING When to activate EMS Adverse effects: Sedation, somnolence Respiratory depression (RR, O 2 sat depression) Dizziness, lack of coordination Typically max q5 days or 5 times/month
43 Antibiotics They don t treat viruses #SavAbx
44 Medications in the School Setting Kristen Nichols, PharmD, BCPS-AQ ID Butler University Riley Hospital for Children
Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationBehavioral Health. Behavioral Health. Prescribing Guidelines
Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine
More informationThe Use of ADHD Medication in the Pediatric Population
The Use of ADHD Medication in the Pediatric Population Shirin Madzhidova, PharmD Pediatric Pharmacotherapy Fellow Nova Southeastern University Objectives Discuss the importance of treatment with medications
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationEvidence-Based Pharmacotherapy. Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center
Evidence-Based Pharmacotherapy Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center CME Disclosure I have no personal financial relationships in any commercial interest related to
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More informationPharmacologic Management of ADHD
Pharmacologic Management of ADHD CHADD Presentation April 13, 2015 Peter J Chung, MD, FAAP Developmental-Behavioral Pediatrician* Assistant Clinical Professor of Pediatrics University of California Irvine
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationADHD: A Focus On Drug Therapy
ADHD: A Focus On Drug Therapy MARY WORTHINGTON, PHARM.D., BCPS MCWHORTER SCHOOL OF PHARMACY BIRMINGHAM, ALABAMA SEPTEMBER 13, 2013 Outpatient Prescription Drug Utilization in US Children, 2002-2010 90
More information2013 Virtual AD/HD Conference 1
Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com
More informationAD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationADHD Medications: Basics. David Benhayon MD, PhD
ADHD Medications: Basics David Benhayon MD, PhD Goals & Objectives Understand basic classes of stimulants and equivalents Be exposed to role of nonstimulant alternatives Discuss the role of therapy in
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationAn Overview on the Use of Psychotropic Medications
An Overview on the Use of Psychotropic Medications Marilyn B. Benoit, M.D. Chief Clinical Officer SVP, Clinical & Professional Affairs Classes of Medications Antidepressants Anti-anxiety Mood stabilizers
More informationDose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.
MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX
A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,
More informationMental Illness. Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling
Mental Illness Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling Moodiness Changing Bodies Narcissism Self-Esteem Ignorant Naïve Insecure Self-Centered Independent Adolescence Disorders Affecting
More informationThings You Might Not Know About Psychotropic Medications But Wish You Did
Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and
More informationCentral Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
More informationManaging the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center
Managing the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center Abstract: The majority of boys and many girls with fragile X
More informationParents Guide to ADHD Medications. Copyright Child Mind Institute
Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive
More informationADHD Explanation 5: Medications used in ADHD
ADHD Explanation 5: Medications The aim of treatment is efficient functioning and achieving goals in life It is most important to find the dose of medications that works best As children grow they may
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder
Cynthia King, MD Associate Professor of Psychiatry UNMSOM Autism Spectrum Disorder 1 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM
Cynthia King, MD Associate Professor of Psychiatry UNMSOM 1 2 Autism Spectrum Disorder 3 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More informationHumberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor
The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry
More informationMRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist
MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:
More informationStimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information
Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More informationChild/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 2009 National Child/Adolescent Attention-Defict/ Hyperactivity
More informationADHD Medications Table
Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common
More informationADHD: Management Update
4/5/17 Conflicts of Interest ADHD: Management Update I have no conflicts to disclose. Jennifer R. Walton, MD, MPH, FAAP April 7, 2017 ADHD: DSM-5 Definition Objectives To briefly review ADHD diagnostic
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationSTATUS EPILEPTICUS IN CHILDREN
STATUS EPILEPTICUS IN CHILDREN Kathy Hunter Sprott, PharmD, BCPS, BCPPS Clinical Pharmacy Specialist Pediatric Transplant and General Pediatrics February 20 th, 2019 Disclosure Statement I have no financial
More informationChild/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 202 National Child/Adolescent Attention-Defict/ Hyperactivity
More informationThe Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD
The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD Damon Korb, MD Behavioral and Developmental Pediatrician Director of the Center for Developing Minds Los Gatos,
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More information35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
More informationMedications in Autism: What We Know and Don't Know
Medications in Autism: What We Know and Don't Know Jeremy Veenstra-VanderWeele, M.D. Mortimer D. Sackler, M.D., Associate Professor Center for Autism and the Developing Brain Sackler Institute for Developmental
More information11/2/2016 INSIDE THE MIND OF A CHILD PSYCHIATRIST: PROBLEM BEHAVIORS IN CHILDREN WITH AUTISM FACULTY DISCLOSURE
FACULTY DISCLOSURE INSIDE THE MIND OF A CHILD PSYCHIATRIST: PROBLEM BEHAVIORS IN CHILDREN WITH AUTISM KristinDawson, MD Assistant Professor University of Kentucky No commercial conflicts of Interest Salary
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationADHD Stimulant Step Therapy Program
ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationClonidine extended-release tablets for the treatment of ADHD
Clonidine extended-release tablets for the treatment of ADHD Joan Daughton*, Lindsey Corr, Howard Liu & Madeline West Practice points Stimulant medications remain the first-line treatment for ADHD. Based
More informationASD (hyperactivity) 3 rd LINE TREATMENT Initial liquid dose mg 2. - ADHD symptoms without sleep
Generic Name Label Name Dosing by Disorder RITALIN, RITALIN LA, CONCERTA, METADATE ER, 2 ND LINE TREATMENT 2 ND LINE TREATMENT METADATE CD, MPH ER, Initial liquid dose 1-5 mg 1,2 Initial liquid dose 1-5mg
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More informationChild & Adolescent Psychiatry (a brief overview)
Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationADHD Part II: Managing Comorbities
ADHD Part II: Managing Comorbities Brett Johnson, MD Staff Psychiatrist Rady Children s Behavioral Crisis Center Assistant Clinical Professor (Voluntary), UCSD January 26, 2011 Financial Disclosure I have
More informationPharmacy Medical Necessity Guidelines: CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationMedically Accepted Indications for Pediatric Use of Psychotropic Medications by
Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:
More informationPharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007
Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual
More informationAlpha-2 Agonists. Antipsychotics
Table 5: Randomized Controlled Trials of Psychotropic Medications in Children and Adolescents with ASD Agent Study Target Symptoms Dose Demographics Significant Side Clonidine Guanfacine Jaselskis et al.,
More information4/11/2018. Attention Deficit Hyperactivity Disorder. ADHD is not a real disorder. History of ADHD and Stimulants. Disclosure.
Disclosure I have no conflicts of interests to disclose Attention Deficit Hyperactivity Disorder No affiliations or financial disclosures with pharmaceutical manufacturers Off-label use of drugs will be
More informationADHD:Updates and Practical Suggestions
:Updates and Practical Suggestions Elizabeth Reeve MD HealthPartners Medical Group Disclosure I have no financial disclosures I may be talking about non FDA approved indications for medications Elizabeth.A.Reeve@HealthPartners.com
More informationAutism: Improving Health Care Outcomes
AUTISM AWARESS CONFERENCE Lewis County Autism Coalition 23 September 2011 Autism: Improving Health Care Outcomes Glenn C. Tripp, M.D. Developmental Behavioral Pediatrics Medical Director, Developmental
More informationPractical Psychopharmacology for More Complex Mental Health Presentations
MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 1: Stimulants Dr. Ajit Ninan & Joel Lamoure 1 Practical Psychopharmacology for More
More informationAdapted from: Best Practices for Medication Management for Children & Adolescents in Foster Care. October 2015
Adapted from: Best Practices for Medication Management for Children & Adolescents in Foster Care October 2015 Psychotropic Medications Key Information Purpose: This document is designed for any reader
More informationJennifer Zarcone. Kennedy Krieger Institute and Johns Hopkins School of Medicine
Jennifer Zarcone Kennedy Krieger Institute and Johns Hopkins School of Medicine 1 2 Estimated that between 20% to 45% of people with autism and ID are taking psychotropic medication 14% 30% are taking
More informationOhio Psychotropic Medication Quality Improvement Collaborative. Minds Matter. Toolkit. for You and Your Family. This is the property of
Minds Matter Ohio Psychotropic Medication Quality Improvement Collaborative Minds Matter Toolkit for You and Your Family This is the property of About Minds Matter Minds Matter is a project to help teens,
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationDisclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013
A Rational Approach to Psychopharmacology Disclosure Statement Full time employed physician with MaineGeneral Medical Center in Waterville and Augusta No conflicts of interest to disclose Goals Promote
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationPsychostimulant and non-stimulant agents address the symptoms of ADHD, substantial evidence shows
Psychostimulant and non-stimulant agents address the symptoms of ADHD, substantial evidence shows Tanya E. Froehlich, MD, MS Associate Professor Department of Pediatrics Division of Developmental and Behavioral
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Brand Name Medication Requests Non-Formulary Medications GMH/SA and Non- 19/21 SMI Mercy Care requires use of generic agents that are considered therapeutically equivalent by the FDA. For authorization
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationWhat About Health 3: Challenging Behaviors
The title of this presentation is What About Health. I m. In this presentation I will discuss a number of health and mental health issues related to children with ASD. 1 Now I am going to switch to discussing
More informationTo properly care for a student diagnosed with a seizure disorder in the school setting/school Age Child Care, the following must occur:
STUDENTS October 10, 2018 STUDENTS Management of Epileptic Seizures in the School Setting/School Age Child Care I. A seizure disorder or epilepsy is a chronic condition that is characterized by recurrent
More informationPharmacotherapy of ADHD with Non-Stimulants
Pharmacotherapy of ADHD with Non-Stimulants Timothy E. Wilens, M.D. Chief, Division of Child and Adolescent Psychiatry, (Co)Director of Center for Addiction Medicine, Massachusetts General Hospital Massachusetts
More informationPerspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY Volume 22 Number 10 October 2016 T Amphetamine Orally Disintegrating Tablets: Another Option for the Treatment of Attention Deficit Hyperactivity Disorder Marcia L. Buck, PharmD,
More informationFacts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationAsk The Shrink: ADHD
Ask The Shrink: ADHD Theodore A. Petti, MD Professor of Psychiatry Division of Child and Adolescent Psychiatry Robert Wood Johnson Medical School PPC Hub Psychiatrist Hackensack Meridian Hubs @ Saint Peter'
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More information